

1. [China assures greater market access to products of Indian companies](#) – The Economic Times

China has assured India of greater market access in a move that could help bridge India's mounting bilateral trade deficit with the Asian giant.

In 2015-16, India's exports to China were \$9 billion, while imports were \$61.7 billion, leaving a trade deficit of \$52.7 billion. Sitharaman sought greater market access for Indian goods, especially for rice and pharmaceutical products, and expressed concerns at the long drawn procedures for clearances that tend to frustrate Indian companies seeking business opportunities in China.

The Chinese minister said recently his country had quickened the pace of granting clearances while importing of Indian pharmaceutical products. China also assured India ahead of the Regional Comprehensive Economic Partnership meeting, which it is hosting, that the country's concerns on a 'single undertaking' will be duly taken on board with services being an integral part of the cooperation agreement.

Similar report-

- [China assures wider market access for Indian products](#) – Mint

1. [China assures greater market access to products of Indian companies](#) – The Economic Times
2. [Govt Asks NPPA To Fix Sky Rocketing Prices Of Three Life Saving Drugs](#) – The Times of India
3. [Alarming! 50% rise in diabetes deaths across India over 11 years](#) – The Economic Times
4. [Gujarat gets 3 pharma parks](#) – The Times of India
5. [Exito Media Concepts announces fifth edition of Pharma Innovation and Technology Summit](#) – Business Standard
6. [Lupin in pact with Boehringer Ingelheim to market diabetic drug](#) – Mint
7. [Health ministry's indifferent attitude delays recognition of Indian Pharmacopoeia in Ghana](#) – Pharmabiz.com
8. [NPPA asks medical devices cos again to provide data of notified devices to monitor prices](#) – Pharmabiz.com

2. [Govt Asks NPPA To Fix Sky Rocketing Prices Of Three Life Saving Drugs](#) – The Times of India

So the good news is that government has asked the National Pharmaceutical Pricing Authority (NPPA) to re-fix the prices of three really important drugs- Phenytoin, Propanolol and Cefotaxime — that are under government price control. Phenytoin is an anti-epilepsy medicine, which works by slowing down impulses in the brain that causes seizures. Propanolol is used to treat high blood pressure, irregular heartbeats, shaking (tremors), and other conditions. It is also used after a heart attack to improve the chance of survival. Cefotaxime is an antibiotic drug. After much thought, the Department of Pharmaceuticals (DoP) passed the orders on these three drugs on October 6. The NPPA works under the DoP.

3. [Alarming! 50% rise in diabetes deaths across India over 11 years](#) – The Economic Times

With a genetic predisposition brought to the fore by changing lifestyles, deaths due to diabetes increased 50 per cent in India between 2005 and 2015, and is now the seventh-most common cause of death in the country, up from 11th rank in 2005, according to data published by the Global Burden of Disease (GBD). Ischemic heart disease continues to be the highest cause of death, followed by chronic obstructive pulmonary disease, cerebrovascular disease, lower respiratory

infection, diarrhoeal diseases and tuberculosis. In 2015, 346,000 people died of diabetes, which caused 3.3 per cent of all deaths that year, with an annual increase of 2.7 per cent from 1990, according to the GBD study.

4. [Gujarat gets 3 pharma parks – The Times of India](#)

The Centre on Thursday offered to develop three pharma sector parks or clusters in Gujarat and promised funds to develop pharma, bulk drugs and medical devices parks in the state. The Gujarat government on the other hand also expressed its commitment to take concrete actions in the direction. The Centre has planned to develop six pharma clusters in India, where the cost of infrastructure creation will be borne by the Union government. Of these, Gujarat now has the chance to develop three. "If you want to set up parks for formulations or bulk drugs or medical devices in Gujarat, government of India will provide finance for all the three parks," Union minister for chemicals and fertilisers, Ananth Kumar, said at the 7th edition of Pharm India 2016 in Ahmedabad. The exhibition has been organised by Indian Drug Manufacturers Association (IDMA).

5. [Exito Media Concepts announces fifth edition of Pharma Innovation and Technology Summit – Business Standard](#)

With a CAGR of 14 percent, Indian Pharmaceutical Industry will reach an annual turnover of USD 47.06 Billion by 2018. An industry predominantly focused on Generics is soon set to diversify its product portfolio to more than 500 APIs, 60,000 generics, CRAM and clinical services across the globe. The sector sees a continuous support from the government as well, with revised amendments in the patent act of 2002, increased expenditure in the healthcare sector as claimed by National Health Policy Draft 2015.

6. [Lupin in pact with Boehringer Ingelheim to market diabetic drug – Mint](#)

Lupin Ltd, India's third largest drugmaker, Thursday said it formed an alliance with Germany's Boehringer Ingelheim GmbH to co-market the latter's diabetic drug empagliflozin in India. As per the agreement, Lupin will market and sell empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force. Boehringer Ingelheim will continue to sell empagliflozin under the brand name Jardiance through its existing sales force and network. Boehringer Ingelheim and Lupin had earlier signed a partnership for marketing another diabetic drug linagliptin in October 2015.

Similar reports-

- [Boehringer Ingelheim, Lupin tie up to co-market anti-diabetes drug – The Times of India](#)
- [Boehringer Ingelheim India and Lupin enter agreement to market diabetes drug – The Economic Times](#)
- [Boehringer Ingelheim, Lupin sign pact for diabetes drug – Business Standard](#)

7. [Health ministry's indifferent attitude delays recognition of Indian Pharmacopoeia in Ghana – Pharmabiz.com](#)

The recognition of Indian Pharmacopoeia (IP) in Ghana is getting inordinately delayed, thanks to the indifferent attitude of the Union health ministry. While the Ghana government is waiting for the final decision from the Indian government, the health ministry is showing no urgency in taking a final call on the issue, which will reduce their product development cost and will also reduce drug registration time of both the countries.

8. [NPPA asks medical device cos again to provide data of notified devices to monitor prices – Pharmabiz.com](#)

The National Pharmaceutical Pricing Authority (NPPA) has once again asked the medical device manufacturers in the country to provide information/data in respect of notified medical devices, manufactured or imported or marketed by these companies for monitoring of the price movement of these notified medical devices as 'Drugs' under DPCO, 2013.